
Vektor Medical provides a non-invasive AI tool that maps cardiac arrhythmias from standard 12‑lead ECGs to help physicians locate arrhythmia sources and guide treatment. The company’s FDA-cleared and CE-marked vMap product uses machine learning models and signal-processing algorithms (implemented with AI/ML technologies and Python) to generate beat-by-beat 2D and 3D maps across all four heart chambers. vMap is delivered as a SaaS clinical workflow tool for electrophysiologists and hospitals and integrates into procedural workflows used during cardiac ablation planning and guidance. Clinical studies reported reductions in procedure duration, time to ablation, and fluoroscopy usage alongside improved patient outcomes. Vektor targets the cardiac electrophysiology market by enabling faster, more targeted ablation and greater procedural efficiency.

Vektor Medical provides a non-invasive AI tool that maps cardiac arrhythmias from standard 12‑lead ECGs to help physicians locate arrhythmia sources and guide treatment. The company’s FDA-cleared and CE-marked vMap product uses machine learning models and signal-processing algorithms (implemented with AI/ML technologies and Python) to generate beat-by-beat 2D and 3D maps across all four heart chambers. vMap is delivered as a SaaS clinical workflow tool for electrophysiologists and hospitals and integrates into procedural workflows used during cardiac ablation planning and guidance. Clinical studies reported reductions in procedure duration, time to ablation, and fluoroscopy usage alongside improved patient outcomes. Vektor targets the cardiac electrophysiology market by enabling faster, more targeted ablation and greater procedural efficiency.
Product: vMap — FDA-cleared, CE-marked AI tool that maps arrhythmias from 12-lead ECGs to guide ablation
Headquarters: San Diego, California
Founded: 2017
Latest known financing: Series A co-led by Solas BioVentures and TVM Capital Life Science
Cardiac arrhythmia diagnosis and guidance for catheter ablation procedures.
2017
Medical Equipment Manufacturing
16000000
Series A announced as $16M; listed as co-led by Solas BioVentures and TVM Capital Life Science.
“Company announced Series A co-led by Solas BioVentures and TVM Capital Life Science”
| Company |
|---|